Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01075321 · OUTCOME

Duration of Response for All Eligible Patients

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · Source last updated 2020-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 5 years

What was measured

Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.

Analysis population: All eligible patients that began study treatment and evaluated as a CR, PR or MR during treatment were included in this analysis.

Groups in this outcome

All Patients (Everolimus and Lenalidomide)

Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients (Everolimus and Lenalidomide)15

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients (Everolimus and Lenalidomide)14.7Not reported2.822.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2.8
        upper Limit
        22.0
        value
        14.7
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
description
Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    All Patients (Everolimus and Lenalidomide)
param Type
MEDIAN
population Description
All eligible patients that began study treatment and evaluated as a CR, PR or MR during treatment were included in this analysis.
reporting Status
POSTED
time Frame
Up to 5 years
title
Duration of Response for All Eligible Patients
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice